Lexeo Therapeutics (LXEO) Stock Price, News & Analysis

Company Overview

Lexeo Therapeutics, Inc. is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments. Lexeo’s lead programs are designed to optimize receptor selectivity and pharmacokinetics, with the goal of delivering rapid onset of action and durable therapeutic benefits in both inpatient and outpatient settings.

To advance its clinical development efforts, Lexeo collaborates with academic institutions and contract research organizations across North America and Europe. These partnerships support ongoing Phase 1 and Phase 2 studies, as well as formulation and biomarker development activities that underpin the company’s regulatory strategy.

Headquartered in the United States, Lexeo Therapeutics is led by a management team with extensive experience in neuroscience research, drug development and regulatory affairs. The company aims to address significant unmet needs in mental health by translating cutting‐edge science into safe, effective treatments for patients worldwide.

Key Stats

• Today's Range: $5.02 to $5.39
• 50-Day Range: $3.67 to $5.02
• 52-Week Range: $1.45 to $11.72
• Volume: 338,894 shs
• Average Volume: 625,200 shs
• Market Capitalization: $283.50 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.33
• Consensus Rating: Buy

Lexeo Therapeutics Stock Analysis - MarketRank™

Lexeo Therapeutics scored higher than 48% of companies evaluated by MarketBeat, and ranked 617th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Buy

Consensus Rating

Lexeo Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Lexeo Therapeutics has a consensus price target of $15.33, representing about 192.1% upside from its current price of $5.25.

Amount of Analyst Coverage

Lexeo Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Lexeo Therapeutics are expected to grow in the coming year, from ($3.14) to ($2.78) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Lexeo Therapeutics is -1.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lexeo Therapeutics is -1.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Lexeo Therapeutics has a P/B Ratio of 1.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.05% of the float of Lexeo Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Lexeo Therapeutics has a short interest ratio ("days to cover") of 10.2, which indicates bearish sentiment.

Change versus previous month

Short interest in Lexeo Therapeutics has recently increased by 0.57%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lexeo Therapeutics does not currently pay a dividend.

Dividend Growth

Lexeo Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

12.05% of the float of Lexeo Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Lexeo Therapeutics has a short interest ratio ("days to cover") of 10.2, which indicates bearish sentiment.

Change versus previous month

Short interest in Lexeo Therapeutics has recently increased by 0.57%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: N/A

News Sentiment

Lexeo Therapeutics has a news sentiment score of 1.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Lexeo Therapeutics this week, compared to 3 articles on an average week.

Search Interest

Only 2 people have searched for LXEO on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Lexeo Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $30,696.00 in company stock.

Percentage Held by Insiders

Only 5.30% of the stock of Lexeo Therapeutics is held by insiders.

Percentage Held by Institutions

60.67% of the stock of Lexeo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LXEO Stock Analysis - Frequently Asked Questions

How have LXEO shares performed this year?

Lexeo Therapeutics' stock was trading at $6.58 at the start of the year. Since then, LXEO shares have decreased by 20.2% and is now trading at $5.25.

How were Lexeo Therapeutics' earnings last quarter?

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) announced its quarterly earnings data on Thursday, August, 14th. The company reported ($0.60) EPS for the quarter, topping analysts' consensus estimates of ($0.64) by $0.04.

When did Lexeo Therapeutics IPO?

Lexeo Therapeutics (LXEO) raised $100 million in an initial public offering (IPO) on Friday, November 3rd 2023. The company issued 9,090,910 shares at a price of $11.00 per share.

Who are Lexeo Therapeutics' major shareholders?

Top institutional investors of Lexeo Therapeutics include Frazier Life Sciences Management L.P. (13.33%), Balyasny Asset Management L.P. (12.08%), Affinity Asset Advisors LLC (10.81%) and Vestal Point Capital LP (9.72%). Insiders that own company stock include Fund Vi LP Omega, Richard Nolan Townsend, Eric Adler, Jose Manuel Otero and Tai Sandi See.
View institutional ownership trends.

How do I buy shares of Lexeo Therapeutics?

Shares of LXEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Lexeo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Lexeo Therapeutics investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Netflix (NFLX) and Home Depot (HD).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 9/08/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LXEO
• Previous Symbol: NASDAQ:LXEO
• CIK: 1907108
• Web: www.lexeotx.com
• Phone: 212-547-9879
• Fax: N/A
• Employees: 58
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Lexeo Therapeutics: $15.33
• High Price Target: $20.00
• Low Price Target: $9.00
• Potential Upside/Downside: +192.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.26)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$98.33 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -94.65%
• Return on Assets: -73.36%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.43
• Quick Ratio: 4.43

Sales & Book Value

• Annual Sales: $650 thousand
• Price / Sales: 436.07
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.53 per share
• Price / Book: 1.49

Miscellaneous

• Outstanding Shares: 54,000,000
• Free Float: 51,139,000
• Market Cap: $283.45 million
• Optionable: Not Optionable
• Beta: 1.36